ArticleInternational journal of nanomedicine2026
Royal Jelly-Derived Extracellular Vesicles: Key Bioactive Components Mediating Anti-Hepatocellular Carcinoma Activity.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural Products and Traditional Chinese Medicine in Hepatocellular Carcinoma: From Pharmacological Mechanisms to Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the role of royal jelly derived extracellular vesicles (RJEVs) as key active components contributing to the anti-hepatocellular carcinoma (HCC) effects of royal jelly and to elucidate the underlying mechanisms. Patients and Methods: This study used H22 tumor-bearing mice as an in vivo model. RJEVs were isolated and identified and their effects were evaluated after oral administration. Analyses included the assessment of liver-targeting properties, immune and antioxidant responses, gut microbiota composition (specifically Muribaculaceae abundance), and short-chain fatty acid metabolism. This study also examined the influence of RJEVs on translation-related signaling networks and the Phosphatidylinositol 3-kinase (PI3K) / Protein Kinase B (AKT) signaling pathway to determine their role in promoting tumor cell apoptosis. Results: Orally administered RJEVs exhibited liver-accumulating properties in H22 tumor-bearing mice and demonstrated moderate antitumor efficacy. They enhanced immune and antioxidant responses, increased the abundance of Muribaculaceae, modulated gut microbiota composition, and improved short-chain fatty acid metabolism. Mechanistically, RJEVs synergistically regulate translation-related signaling networks and remodel the immune microenvironment, ultimately promoting tumor cell apoptosis via the PI3K/AKT signaling pathway. Conclusion: These findings provide novel insights into the functional role of royal jelly by identifying RJEVs as important bioactive constituents that contribute to the anti-HCC effects by modulating the immune microenvironment, gut microbiota, and PI3K/AKT signaling. This offers both theoretical and methodological advances in research on the bioactive components of bee products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.